Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
0 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with a monoclonal antibody against immune checkpoint molecule TIM-3.
17 Citations
70 Claims
-
1-48. -48. (canceled)
-
49. A method for treating a human cancer patient comprising:
-
(a) administering to the patient a recombinant poxvirus encoding a polypeptide comprising at least one tumor-associated antigen (TAA); and (b) administering to the patient a TIM-3 antagonist - View Dependent Claims (50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)
-
-
63. A pharmaceutical combination for treating cancer in a human patient, comprising:
- (a) a recombinant poxvirus encoding a polypeptide comprising at least one tumor-associated antigen (TAA); and
(b) a TIM-3 antagonist. - View Dependent Claims (64, 65, 66, 67, 68, 69)
- (a) a recombinant poxvirus encoding a polypeptide comprising at least one tumor-associated antigen (TAA); and
-
70. A method for treating a human cancer patient as part of a homologous or heterologous prime-boost regimen, the method comprising:
-
(a) administering to the patient a priming dose of a recombinant poxvirus encoding a polypeptide comprising at least one tumor-associated antigen (TAA) in combination with a TIM-3 antagonist; and (b) administering to the patient one or more subsequent boosting doses of a recombinant poxvirus encoding a polypeptide comprising at least one tumor-associated antigen (TAA) in combination with a TIM-3 antagonist; wherein, as part of a homologous prime-boost regimen, the recombinant poxvirus of (a) and (b) comprise the same recombinant poxvirus;
orwherein, as part of a heterologous prime-boost regimen, the recombinant poxvirus of (a) and (b) comprise a different recombinant poxvirus.
-
Specification